The short version of WADA fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
The very large incentives given to pharmaceutical companies to produce orphan drugs have led to the impression that the financial support afforded to make these drugs possible is akin to abuse. Because drugs can be used to treat multiple conditions, companies can take drugs that were filed with their government agency as orphan drugs to receive financial assistance, and then market it to a wide population to increase their profit margin. For example AstraZeneca's cholesterol drug Crestor was filed as a treatment for the rare disease pediatric familial hypercholesterolemia. After the drug was approved for orphan drug designation, and AstraZeneca had received tax breaks and other advantages, AstraZeneca later applied and received FDA approval for the drug to be used to treat cholesterol in all diabetics.
=== Vibrational spectroscopy === The vibrational spectroscopy methods used to analyze the end groups of a polymer are infrared (IR) and Raman spectroscopy. These methods are useful in fact that the polymers do not need to be soluble in a solvent and spectra can be obtained simply from solid material. A disadvantage of the technique is that only qualitative data is typically obtained on the identification end groups.
=== Availability === Nemonapride is marketed only in Japan and China. It was also under development for use in other countries, such as France, but development in other countries was discontinued. There are no further plans for nemonapride to be developed for use in the United States, the United Kingdom, or Europe.
=== Fermi function === The Fermi function that appears in the beta spectrum formula accounts for the Coulomb attraction / repulsion between the emitted beta and the final state nucleus. Approximating the associated wavefunctions to be spherically symmetric, the Fermi function can be analytically calculated to be:
Sources: en.wikipedia.org
=== Sedation === The relative effectiveness of lorazepam in preventing new memory formation, along with its ability to reduce agitation and anxiety, makes it useful as premedication. It is given before a general anesthetic to reduce the amount of anesthetic required or before unpleasant awake procedures, such as in dentistry or endoscopies, to reduce anxiety, increase compliance, and induce anterograde amnesia for the procedure. Orally administered lorazepam is given 90 to 120 minutes before procedures, and intravenous lorazepam is given up to 10 minutes before procedures. Lorazepam is sometimes used as an alternative to midazolam in palliative sedation. In intensive care units, lorazepam is sometimes used to produce anxiolysis, hypnosis, and amnesia. Lorazepam is sometimes used for individuals receiving mechanical ventilation. In critically ill people, propofol has been found to be superior to lorazepam both in effectiveness and overall cost; as a result, the use of propofol for this indication is now encouraged, whereas the use of lorazepam is discouraged.
Polyprotic acids, also known as polybasic acids, are able to donate more than one proton per acid molecule, in contrast to monoprotic acids that only donate one proton per molecule. Specific types of polyprotic acids have more specific names, such as diprotic (or dibasic) acid (two potential protons to donate), and triprotic (or tribasic) acid (three potential protons to donate). Some macromolecules such as proteins and nucleic acids can have a very large number of acidic protons. A diprotic acid (here symbolized by H2A) can undergo one or two dissociations depending on the pH. Each dissociation has its own dissociation constant, Ka1 and Ka2.
usaspending.gov - interactive official chart Congressional Budget Office The Federal Budget from the White House, OMB U.S. Federal Budget collected news and commentary at The New York Times Budget of the United States Government and various supplements from 1923 to the present. Federal Budget Receipts and Outlays from 1930 to the present. Federal Budgets of the United States Government from fiscal years 1923 to the present.
== Therapeutic use == As a paradox to the symptoms after a bee sting, bee venom is used for treatment of pain, inflammation (e.g. rheumatoid arthritis) and multiple sclerosis. Tertiapin may contribute to this effect by prolonging the depolarization phase by blocking the BK channels. Eventually this will lead to inactivation of the voltage-gated Na+ channels of the dorsal root ganglion neurons, reducing sensory transmission to the central nervous system. Excessive stimulation with acetylcholine can induce an AV-block in the heart as shown in guinea pigs, which can be prevented by blockage of the KAch channels by tertiapin. This suggests a possible therapeutic role in excessive parasympathetic innervation or inferior myocardial infarction.
== Performing with the Grateful Dead == In early 1970, Lagin initiated a correspondence with Jerry Garcia after seeing the Grateful Dead at the Boston Tea Party in 1969. In May 1970, he helped facilitate a concert and free live outdoor performance featuring the band at MIT that coincided with the Kent State shootings. That summer, Lagin, at Garcia's invitation, visited San Francisco and contributed piano to "Candyman" during the American Beauty album sessions, played in several jams, and started what would become close friendships with Garcia, bassist Phil Lesh, and David Crosby. From 1970 to 1975, Lagin contributed Hammond B3 organ, electric piano, and clavichord to material of his choice (primarily—but not exclusively—songs with long instrumental passages) at several Grateful Dead concerts. His first performances with the Grateful Dead were on November 5 and November 8, 1970 at the Capitol Theater in Port Chester, New York; his first complete concert was at Boston University's Sargent Gym on November 21, 1970. During many 1974 Grateful Dead concerts over several tours, including Europe, he performed a middle set of electronic music, including parts of his composition Seastones, on computer-controlled analog synthesizers with Phil Lesh on electronically processed bass. Some sets included Jerry Garcia playing guitar filtered through effects processors and Bill Kreutzmann on drums; these sets occasionally segued into the final Grateful Dead set, with Lagin performing with the Dead, including an appearance in The Grateful Dead Movie.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.